The Relevance Of The Research Of Mikhail Blagosklonny On Cancer And Aging

The studies of Mikhail Blagosklonny have always focused on aging along with cancer. He lectures at the Roswell Park Cancer.

The studies of Mikhail Blagosklonny have always focused on aging along with cancer. He lectures at the Roswell Park Cancer Institute which is based in New York. These are based around oncology.

Mikhail Blagosklonny has studied at the First Pavlov State Medical University. This is based in St Petersburg. He earned his Master’s degree in Internal Medicine from here. Then he did his Ph.D. in cardiology as well as experimental medicine from this institution. Read more on templeofthecave.com

He started his professional career in 2002. This was by working as an Associate Professor at the New York Medical College. Later, he became a Senior Scientist with Ordway Research Institute. During this time, he was heading the research strategies unit of the Institute. Mikhail Blagosklonny worked with them till 2009. Then he decided to give lectures on oncology. This was at the Roswell Park Cancer Institute in New York.

Mikhail Blagosklonny conducts research on molecular as well as cellular biology. He is the co-founder of a journal that is covering several medical topics that include mitosis, cancer cell cycling and so on. This journal is called Cell Cycle.

Mikhail Blagosklonny is highly passionate about his research on several topics that are related to cancer. His focus is on those therapies related to cancer that can help in protecting the human cell from any kind of damage. His other research is on biogerontology. This refers to the study of aging in the case of humans. This is why he is interested in producing anti-aging drugs.

There is a hypothesis that has been framed by Mikhail Blagosklonny. It talks about making use of TOR signaling in aging as well as cancer. As per this hypothesis, Rapamycin is a drug that can help in enhancing the lifespan of those who are suffering from cancer. Typically Rapamycin is being used in cancer therapies for reducing the cancer cells multiplication. This drug can reduce the spreading of cancer cells, as well as the immunity of cancer patients. Mikhail Blagosklonny has been recognized for this research in longevity studies by advocating for rapamycin.

In addition to conducting scientific researches, Mikhail Blagosklonny works for several journals as their senior editor. These are namely, Oncotarget, Cell Cycle as well as Aging journals. While Oncotarget refers to an open access journal covering various topics related to oncology, it gets published through Impact Journals. The editors are Mikhail Blagosklonny along with Andrei Gudkov. He is the associate editor of the journal, Cancer Biology and Therapy, too. He is on the editorial board of the journal, Cell Death & Differentiation, too. Check Mikhail’s profile in LinkedIn

Mikhail Blagosklonny is the writer of over 270 articles. These are published in various journals. His publications have been cited by many nearly 25,000 times.

This article was written by forvets